Positive safety studies for NX 1207 for BPH - Nymox Pharma

Nymox Pharmaceutical has released data supporting the positive safety profile of NX 1207, for prostate enlargement (BPH or Benign Prostate Hyperplasia). Recent pharmacokinetic studies using a new blood test for NX 1207 have shown that the drug is undetectable in the blood post-injection, providing strong evidence that, once injected into the prostate, the drug remains confined to the prostate and thus unable to affect other organs such as the liver, kidneys, heart, or testes. These results are consistent with the pharmacological profile of the drug and with the extensive body of safety data from the more than 1,000 men treated with the drug to date demonstrating the absence of any significant drug-related side effects.

In addition, men treated with NX 1207 have not displayed any signs of an allergic or other immune reaction to the drug either on first injection or repeat injection. Extensive clinical immunogenicity testing of men in the Company's pivotal Phase III trials and Phase III repeat injection safety studies have found no evidence of anti-drug antibody formation after exposure to the drug. The Company will present more detailed scientific data from these studies at upcoming medical conferences.